PacBio Appoints New CEO, Announces Major Restructuring & Q2 Results
PACB sits 18% above its 52-week low of $1.09.
Summary
PacBio appointed Mark Van Oene as its new CEO and announced a major restructuring to cut $30M-$40M in annual operating expenses, alongside reporting a wider Q2 net loss.
Updates
· Wiseek News — PacBio delayed cash-flow breakeven to 2028 and set non-GAAP gross margin of 35%-37%, operating expenses of $215M-$220M, and year-end cash of $175M-$185M.
· SEC 10-Q — CFO Jim Gibson adopted a 10b5-1 plan to sell up to 661,685 shares.
· Reuters — Q2 adjusted loss per share was $0.14, a penny worse than consensus, and gross margin compressed to 36% on higher compute costs and lower Revio ASPs. Full-year 2026 revenue guidance of $155M-$165M is below the $180M+ Street estimate.
Key Events · Executive and Board Changes · PACB
-
CEO Transition
Mark Van Oene, previously Chief Operating Officer, has been appointed President and Chief Executive Officer, effective August 5, 2026. He also joins the Board of Directors. Christian Henry stepped down as CEO but will remain on the Board and serve as a Senior Business Advisor through December 31, 2026.
-
Significant Restructuring Plan
The Board approved a restructuring plan, including a reduction of approximately 40 employees (8% of the workforce). This is expected to reduce annualized operating expenses by $30 million to $40 million by the end of 2027, with estimated pre-tax charges of $2.0 million in Q3 2026.
-
Q2 2026 Financial Results
The company reported a GAAP net loss of $44.7 million on $39.0 million in revenue for Q2 2026, compared to a net loss of $41.9 million on $39.8 million revenue in Q2 2025. Full-year 2026 revenue guidance is set between $155 million and $165 million.
-
New CEO Compensation & Severance
New CEO Mark Van Oene will receive an annual base salary of $743,000, a 100% target bonus opportunity, and equity awards valued at $2,250,000. Outgoing CEO Christian Henry will receive a lump sum cash payment of $1,161,685.50 upon signing a separation agreement, in addition to continued salary and equity vesting during his advisory period.
Analysis · PACB · Industrial Applications And Services
Pacific Biosciences announced a significant leadership transition, promoting COO Mark Van Oene to President and CEO, replacing Christian Henry. Concurrently, the company initiated a substantial restructuring plan, including an 8% workforce reduction, aimed at achieving $30 million to $40 million in annualized operating expense reductions by the end of 2027. These proactive strategic changes are critical for the company's future financial health, especially as it reported a wider net loss of $44.7 million for Q2 2026, despite some positive operational highlights like new product rollouts.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PACB was trading at $1.29 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $403.8M. The 52-week trading range was $1.09 to $2.73. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.